Utilization of Rad51C promoter for transcriptional targeting of cancer cells

Oncotarget

Volumn 5, Issue 7, 2014, Pages 1805-1811

  Cao, Yan ^a   Xu, Yan ^a   Zhang, Lei ^a   Li, Zhen ^a   Jiang, Ying ^a   Tian, Xiao ^b   Seluanov, Andrei ^b   Gorbunova, Vera ^b   Mao, Zhiyong ^a  

^a TONGJI UNIVERSITY   (China)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Cancer therapy; DNA double strand break repair; Homologous recombination; Rad51 paralogs; Rad51C promoter

Indexed keywords

DIPHTHERIA TOXIN; DIPHTHERIA TOXIN A; MESSENGER RNA; RAD51 PROTEIN; RAD51B PROTEIN; RAD51C PROTEIN; RAD51D PROTEIN; RAD52 PROTEIN; UNCLASSIFIED DRUG; DIPHTHERIA TOXIN FRAGMENT A; DNA BINDING PROTEIN; FIREFLY LUCIFERASE; PEPTIDE FRAGMENT; RAD51B PROTEIN, HUMAN; RAD51C PROTEIN, HUMAN; RAD51D PROTEIN, HUMAN; RAD52 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CELL KILLING; CELL SPECIFICITY; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENOME SIZE; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION; BIOSYNTHESIS; CELL SURVIVAL; GENE FUSION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY;

CELL LINE, TUMOR; CELL SURVIVAL; DIPHTHERIA TOXIN; DNA-BINDING PROTEINS; GENE FUSION; HUMANS; LUCIFERASES, FIREFLY; MOLECULAR TARGETED THERAPY; PEPTIDE FRAGMENTS; PROMOTER REGIONS, GENETIC; RAD52 DNA REPAIR AND RECOMBINATION PROTEIN; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRANSFECTION; UP-REGULATION;

EID: 84899024225     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1792     Document Type: Article

References (29)

1. Abdul-Ghani R, Ohana P, Matouk I, Ayesh S, Ayesh B, Laster M, Bibi O, Giladi H, Molnar-Kimber K, Sughayer MA, de Groot N and Hochberg A. Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Molecular therapy: the journal of the American Society of Gene Therapy. 2000; 2(6):539-544.
2. Latham JP, Searle PF, Mautner V and James ND. Prostatespecific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer research. 2000; 60(2):334-341.
3. Hine CM, Seluanov A and Gorbunova V. Use of the Rad51 promoter for targeted anti-cancer therapy. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(52):20810-20815.
4. Hine CM, Seluanov A and Gorbunova V. Rad51 promotertargeted gene therapy is effective for in vivo visualization and treatment of cancer. Molecular therapy: the journal of the American Society of Gene Therapy. 2012; 20(2):347- 355.
5. Maacke H, Jost K, Opitz S, Miska S, Yuan Y, Hasselbach L, Luttges J, Kalthoff H and Sturzbecher HW. DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene. 2000; 19(23):2791- 2795.
6. Raderschall E, Stout K, Freier S, Suckow V, Schweiger S and Haaf T. Elevated levels of Rad51 recombination protein in tumor cells. Cancer research. 2002; 62(1):219-225.
7. Mao Z, Jiang Y, Liu X, Seluanov A and Gorbunova V. DNA repair by homologous recombination, but not by nonhomologous end joining, is elevated in breast cancer cells. Neoplasia. 2009; 11(7):683-691.
8. Shinohara A and Ogawa T. Stimulation by Rad52 of yeast Rad51-mediated recombination. Nature. 1998; 391(6665):404-407.
9. Masson JY, Tarsounas MC, Stasiak AZ, Stasiak A, Shah R, McIlwraith MJ, Benson FE and West SC. Identification and purification of two distinct complexes containing the five RAD51 paralogs. Genes & development. 2001; 15(24):3296-3307.
10. Kuznetsov SG, Haines DC, Martin BK and Sharan SK. Loss of Rad51c leads to embryonic lethality and modulation of Trp53-dependent tumorigenesis in mice. Cancer research. 2009; 69(3):863-872.
11. Shu Z, Smith S, Wang L, Rice MC and Kmiec EB. Disruption of muREC2/RAD51L1 in mice results in early embryonic lethality which can Be partially rescued in a p53(-/-) background. Molecular and cellular biology. 1999; 19(12):8686-8693.
12. Deans B, Griffin CS, Maconochie M and Thacker J. Xrcc2 is required for genetic stability, embryonic neurogenesis and viability in mice. The EMBO journal. 2000; 19(24):6675- 6685.
13. Pittman DL and Schimenti JC. Midgestation lethality in mice deficient for the RecA-related gene, Rad51d/Rad51l3. Genesis. 2000; 26(3):167-173.
14. Badie S, Liao C, Thanasoula M, Barber P, Hill MA and Tarsounas M. RAD51C facilitates checkpoint signaling by promoting CHK2 phosphorylation. The Journal of cell biology. 2009; 185(4):587-600.
15. Constantinou A, Davies AA and West SC. Branch migration and Holliday junction resolution catalyzed by activities from mammalian cells. Cell. 2001; 104(2):259-268.
16. Kuznetsov S, Pellegrini M, Shuda K, Fernandez-Capetillo O, Liu Y, Martin BK, Burkett S, Southon E, Pati D, Tessarollo L, West SC, Donovan PJ, Nussenzweig A and Sharan SK. RAD51C deficiency in mice results in early prophase I arrest in males and sister chromatid separation at metaphase II in females. The Journal of cell biology. 2007; 176(5):581-592.
17. Akbari MR, Tonin P, Foulkes WD, Ghadirian P, Tischkowitz M and Narod SA. RAD51C germline mutations in breast and ovarian cancer patients. Breast cancer research: BCR. 2010; 12(4):404.
18. Chung CC, Kanetsky PA, Wang Z, Hildebrandt MA, Koster R, Skotheim RI, Kratz CP, Turnbull C, Cortessis VK, Bakken AC, Bishop DT, Cook MB, Erickson RL, Fossa SD, Jacobs KB, Korde LA, et al. Meta-analysis identifies four new loci associated with testicular germ cell tumor. Nature genetics. 2013; 45(6):680-685.
19. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, Freund M, Lichtner P, Hartmann L, Schaal H, Ramser J, Honisch E, Kubisch C, Wichmann HE, Kast K, Deissler H, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nature genetics. 2010; 42(5):410-414.
20. Pelttari LM, Heikkinen T, Thompson D, Kallioniemi A, Schleutker J, Holli K, Blomqvist C, Aittomaki K, Butzow R and Nevanlinna H. RAD51C is a susceptibility gene for ovarian cancer. Human molecular genetics. 2011; 20(16):3278-3288.
21. Thompson ER, Boyle SE, Johnson J, Ryland GL, Sawyer S, Choong DY, kConFab, Chenevix-Trench G, Trainer AH, Lindeman GJ, Mitchell G, James PA and Campbell IG. Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients. Human mutation. 2012; 33(1):95-99.
22. Mao Z, Bozzella M, Seluanov A and Gorbunova V. Comparison of nonhomologous end joining and homologous recombination in human cells. DNA repair. 2008; 7(10):1765-1771.
23. Fong V, Osterbur M, Capella C, Kim YE, Hine C, Gorbunova V, Seluanov A and Dewhurst S. Adenoviral vector driven by a minimal Rad51 promoter is selective for p53-deficient tumor cells. PloS one. 2011; 6(12):e28714.
24. Nettelbeck DM, Rivera AA, Balague C, Alemany R and Curiel DT. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/ promoter. Cancer research. 2002; 62(16):4663-4670.
25. Chen JS, Liu JC, Shen L, Rau KM, Kuo HP, Li YM, Shi D, Lee YC, Chang KJ and Hung MC. Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer gene therapy. 2004; 11(11):740-747.
26. Yu L, Hamada K, Namba M, Kadomatsu K, Muramatsu T, Matsubara S and Tagawa M. Midkine promoterdriven suicide gene expression and -mediated adenovirus replication produced cytotoxic effects to immortalised and tumour cells. European journal of cancer. 2004; 40(11):1787-1794.
27. Gu J, Kagawa S, Takakura M, Kyo S, Inoue M, Roth JA and Fang B. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer research. 2000; 60(19):5359-5364.
28. Kay MA, Glorioso JC and Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nature medicine. 2001; 7(1):33-40.
29. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4):402- 408.